|
Kyprolis, given in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma following one prior treatment failure received a positive listing recommendation from the pCODR's Expert Review Committee (pERC), providing that provinces negotiate a pricing arrangement that improves the cost-effectiveness of Kyprolis in combination with lenalidomide and dexamethasone. In other words, they agreed there is strong clinical evidence supporting the use of Kyprolis, however the cost needs to be lowered.
The panCanadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process. The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, while using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.
Myeloma Canada would like to thank each and every patient and caregiver who contributed to the patient survey conducted last Fall. Without your input, Myeloma Canada would not have been in the position to best represent your needs, perspectives and comments for the pCODR review process. In fact, the pCODR drug review committee shared very positive comments about the quality of our submission, thanks to all of you!
The pCPA conducts joint provincial/territorial negotiations for brand name drugs in Canada to achieve greater value for publicly funded drug programs for patients. All brand name drugs coming forward for funding through the pCODR is then considered for negotiation through the pCPA. This process can take up to 9 months to conclude. After this negotiation process, each province will ultimately decide to list (or not) a drug based on the negotiated price through the pCPA process.
Should the negotiations between the pCPA and the manufacturer be conclusive, we should see provincial access granted for patients anywhere between 9 to 12 months from now. Myeloma Canada will remain extremely vigilant and work diligently with all stakeholders involved throughout this process to ensure rapid access to all patients who require this new and innovative therapy.
|
